Sports / Entertainment

Strategies for Creating Growth and Value

University of California, Berkeley

This annual gathering of executives in biotechnology, information technology, healthcare, venture capital, academe, government, law and financial services will focus
on changes in healthcare policies, financing, and shareholder expectations and on strategies that best position biotech companies for sustainable growth.
Discussion will also center on next generation technologies and how they will advance science as well as drive fundamental changes in business practices.

Agenda (Revised 6/18/99)

Claremont Room Overlooking San Francisco Bay

Claremont Hotel Ballroom

CAPITAL MARKETS AND FUTURE FINANCING
PROSPECTS FOR LIFE SCIENCE COMPANIES

Venture capital funding of biotech companies continues to rise but not at the record-shattering rates of monies pouring into information technology and Internet-related enterprises. What strategies should biotech companies develop to regain investor confidence, momentum, and growth?

KEYNOTE ADDRESS:

Alfred R. Berkeley President The Nasdaq Stock Market

Laura Tyson, Dean, Hass School of Business

New science and new technology are combining to remake the pharmaceutical industry. This session looks at the forces driving change illustrated by case studies of successful companies that have capitalized on the synergy of collaborative efforts, partnerships and information technologies.

Edward Penhoet, Moderator Founder & Director Chiron Corporation Dean, School of Public Health, UC Berkeley David Robinson CEO Ligand Pharmaceuticals Jim Scopa Managing Director Healthcare Group Deutsche Banc Alex.Brown

William Rastetter CEO IDEC Pharmaceuticals Randal Scott President & CSO Incyte Pharmaceuticals Dr. James N. Woody President Roche BioScience

How do you adapt and transcend the false starts and stops in research and product development ­ a problem endemic in the biotech business. When a company has an abundance of ideas but is short of funding, how does it focus? In the R&D and trial stages of gene and drug discovery and validating targets and drug development, some companies have encountered obstacles and have turned them into substantial opportunities. This discussion looks at case studies with practical, life-saving lessons.

Vaughn Kailian, Moderator President & CEO COR Therapeutics		Pascal Brandys Chairman & CEO Genset
Ron Eastman CEO Geron Ty R. Sagalow Chief Underwriting Officer National Union, AIG		John Martin CEO Gilead Sciences, Inc.

International Sources for Capital Funding: Why Foreign Investors buy U.S. Companies

Chair: Vera Kallmeyer, Veritas Venture Partners LLC

Frank Kung, General Partner, BioAsia Investments

Mark Cochran, Managing Director, MDS Health Ventures

The New World of Corporate Partnering:

Case Study of Aviron/Wyeth Lederle Vaccines

Barbara Kosacz, Partner, Cooley Godward, LLP

Carol Olson, Senior V.P., Commercial Development, Aviron

The Role of the Biotech CFO: How to Take Your Case to the Street

How do you “sell” Wall Street on your unique endeavor at a time when the entire biotech industry is perceived as lackluster by the investment community? Here’s how.

Chair: Deborah Smeltzer, CFO, Genset

Mark Jensen, Managing Partner, Silicon Valley, Arthur Andersen LLP

Timothy C. Fredel, CEO, Biospace.com

Lakeview Club

Welcome Remarks:

Mayor Jerry Brown City of Oakland

THE ECONOMICS OF HEALTHCARE:
ARE WE PLAYING BY NEW RULES?
When Washington sneezes, does the healthcare industry catch the cold? Who pays for the doctors? And who profits from prescription medicines?

KEYNOTE ADDRESS:

Laura Tyson Dean Haas School of Business University of California, Berkeley Former Chairman, President’s Council of Economic Advisors

Capital markets for biotech have become dangerously small. At the same time, too many companies are being formed on the basis of a single scientific idea. So what models will ensure survival? And how do you align the potential of biotech with the goals of investors?

Karen Bernstein, Moderator Editor-in-Chief BioCentury Kurt Von Emster Portfolio Manager Franklin Advisors Dale Pfost CEO Orchid Biocomputer, Inc.

Tom Wiggans CEO Connetics Jim Blair Partner Domain Associates, LLC Larry Stambaugh President and CEO Maxim Pharmaceuticals

Technology and electronic commerce are changing banking, retail, and financial services, offering better realtime options to customers. These same customers will be demanding similar accessibility to healthcare information, products, and providers. How can life science companies use the Internet to achieve better efficiencies in supply chain management, clinical trials, patient treatment, realtime service and sales?

Rich Karlgaard, Moderator Publisher Forbes W. Michael Long CEO Healtheon

Regis McKenna Chairman Regis McKenna Inc. Luther Nussbaum CEO First Consulting Group

The type and pace of biomedical innovation that we can expect is driven by healthcare reimbursement programs. This panel looks at current and proposed policies from Washington and new directions being taken by healthcare systems that will steer future R&D investment and determine not only what companies in the chain — but who in society — will benefit.

Leighton Read, Moderator Chairman & CEO Aviron		Chuck Ludlam V.P. Government Affairs BIO
Walter K. Moore V.P. Government Affairs Genentech, Corp.		David Gollaher Chairman & CEO California HealthCare Institute

ADVICE TO HEALTHCARE AND BIOMEDICAL INNOVATORS: WHY TO STAY THE COURSE

KEYNOTE ADDRESS:

Dr. David M. Lawrence Chairman & CEO Kaiser Foundation Health Plan